Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.
Immunomodulatory agents, including cytokines, monoclonal antibodies, and CpG oligonucleotides, have properties that suggest they have the ability to augment rituximab in the treatment of non-Hodgkin's lymphoma. Although several clinical trials have promising results, no randomized trials of reasonable size have been performed to date, limiting the ability to discern whether combinations of immunomodulatory agents with rituximab impact clinical outcome. Until such trials are mature, we do not recommend using these agents in combination outside of the research setting.
Friedberg
Jonathan W
JW
James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1-4118C, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu
Freedman
Arnold S
AS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors